The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival
Open accessThe DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Abstract
D-type cyclins (D1, D2 and D3) and their associated cyclin-dependent kinases (CDK4 and CDK6) are components of the core cell cycle machinery that drives cell proliferation. Inhibitors of CDK4 and CDK6 are currently being tested in clinical trials for patients with several cancer types, with promising results. Here, using human cancer cells and patient-derived xenografts in mice, we show that the cyclin D3-CDK6 kinase phosphorylates and inhibits the catalytic activity of two key enzymes in the glycolytic pathway, 6-phosphofructokinase and pyruvate kinase M2. This re-directs the glycolytic intermediates into the pentose phosphate (PPP) and serine pathways. Inhibition of cyclin D3-CDK6 in tumour cells reduces flow through the PPP and serine pathways, thereby depleting the antioxidants NADPH and glutathione. This, in turn, increases the levels of reactive oxygen species and causes apoptosis of tumour cells. The pro-survival function of cyclin D-associated kinase operates in tumours expressing high levels of cyclin D3-CDK6 complexes. We propose that measuring the levels of cyclin D3-CDK6 in human cancers might help to identify tumour subsets that undergo cell death and tumour regression upon inhibition of CDK4 and CDK6. Cyclin D3-CDK6, through its ability to link cell cycle and cell metabolism, represents a particularly powerful oncoprotein that affects cancer cells at several levels, and this property can be exploited for anti-cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The cyclin D3/CDK6 kinase complex can phosphorylate 6-phosphofructokinase and pyruvate kinase M2 (Wang et al., 2017).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Wang et al., 2017
In the citing paper
“This has the effect of pushing glycolytic intermediates into the pentose phosphate and serine pathways, and inhibition of CDK6 (through treatment with palbociclib, ribociclib, or knockdown of CDK6) depletes the antioxidants NADPH and glutathione, increasing ROS and apoptosis.”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Wang et al., 2017
In the citing paper
“These cells express very low levels of cyclin D1, cyclin D2, and CDK4, and the proliferative decision is dependent upon cyclin D3 and CDK6 (Wang et al., 2017; Wolowiec et al., 1996).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Wang et al., 2017
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Eng, J. K., McCormack, A. L., & Yates, J. R. (1994) · Journal of the American Society for Mass Spectrometry · doi:10.1016/1044-0305(94)80016-2 · Cited by 6,484
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744
Elias, J. E., & Gygi, S. P. (2007) · Nature Methods · doi:10.1038/nmeth1019 · Cited by 3,925
Self-citationThe M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth
Christofk, H. R., Vander Heiden, M. G., Harris, M. H., Ramanathan, A., Gerszten, R. E., Wei, R., Fleming, M. D., Schreiber, S. L., & Cantley, L. C. (2008) · Nature · doi:10.1038/nature06734 · Cited by 2,820
A tissue-specific atlas of mouse protein phosphorylation and expression
Huttlin, E. L., Jedrychowski, M. P., Elias, J. E., Goswami, T., Rad, R., Beausoleil, S. A., Villén, J., Haas, W., Sowa, M. E., & Gygi, S. P. (2010) · Cell · doi:10.1016/j.cell.2010.12.001 · Cited by 1,778
Self-citationMalumbres, M. (2014) · Genome Biology · doi:10.1186/gb4184 · Cited by 1,654
Beausoleil, S. A., Villén, J., Gerber, S. A., Rush, J., & Gygi, S. P. (2006) · Nature Biotechnology · doi:10.1038/nbt1240 · Cited by 1,577
Self-citationGao, H., Korn, J. M., Ferretti, S., Monahan, J. E., Wang, Y., Singh, M., Zhang, C., Schnell, C., Yang, G., Zhang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3954 · Cited by 1,393
Self-citationAnastasiou, D., Poulogiannis, G., Asara, J. M., Boxer, M. B., Jiang, J.-K., Shen, M., Bellinger, G., Sasaki, A. T., Locasale, J. W., Auld, D. S., et al. (2011) · Science · doi:10.1126/science.1211485 · Cited by 1,190
Quantitative flux analysis reveals folate-dependent NADPH production
Fan, J., Ye, J., Kamphorst, J. J., Shlomi, T., Thompson, C. B., & Rabinowitz, J. D. (2014) · Nature · doi:10.1038/nature13236 · Cited by 1,114
Cited by
Items 301–345 of 345
XTP1 facilitates the growth and development of gastric cancer by activating CDK6
Li, K., Ma, R., Meng, L., Wang, Q., Cao, J., Yuan, D., Sun, T., Li, K., Hao, N., Wang, H., et al. (2023) · Annals of Translational Medicine · doi:10.21037/atm-22-5933 · Cited by 1
“CDK6 inhibitors have been used in the development of antitumor drugs (20,22) .”
Self-citationFox, D. B., Lupo, R., Noteware, L. C., Newcomb, R., Liu, J., Locasale, J. W., Hirschey, M. D., & Alvarez, J. V. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/513994 · Cited by 1
“Recent evidence has shown that inhibition of the glucose dependent oxidative pentose phosphate pathway (PPP), which generates NADPH, is sufficient to induce ROS and cell death in tumor cells (Wang et al., 2017).”
BackgroundThe retinoblastoma protein mediates metabolic reprogramming in lung cancer.
Conroy, L. R. (2020) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/3405 · Cited by 1
Hong, Y., He, W., Zhang, J., Shen, L., Yu, C., Yan, L., Chen, H., Wu, Y., Chen, L., Lyu, J., et al. (2020) · Research Square · doi:10.21203/rs.3.rs-125333/v1 · Cited by 1
“It has also been reported that Palbociclib potentially inhibits both cell cycle entry in human T-ALL as well as disease progression in animal models of T-ALL(7), and Ribociclib could signi cantly reduce tumor growth in nude mice that grafted with patient-derived melanomas(8).”
BackgroundResultDistinct gene regulatory networks govern hematopoietic and leukemia stem cellsPreprint
Zhang, B., Murison, A. J., Varesi, A., Takayama, N., Jin, L., Mbong, N., Schoof, E. M., Xie, S. Z.-J., Mitchell, A., Etchin, J., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.28.614980 · Cited by 1
“In such cells, high levels of reactive oxygen species can induce apoptosis in several tumor types 78 .”
BackgroundPapers of note in Nature 546 (7658)
VanHook, A. M. (2017) · Science Signaling · doi:10.1126/scisignal.aao1168
袁, 晓. (2021) · Advances in Clinical Medicine · doi:10.12677/acm.2021.1112851
Endicott, J. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.737072659.793569640
Therapy-Induced Dormancy and Residual Disease
DiMarco, A. V., Garcia, N. M. G., & Alvarez, J. V. (2022) · Springer eBooks · doi:10.1007/978-3-030-93084-4_10
CDK6 activity in a recurring convergent kinase network motif
Gangemi, C. G., Sabapathy, R. T., & Janovjak, H. (2023) · The FASEB Journal · doi:10.1096/fj.202201344r
Data from Targeting Pyruvate Kinase M2 Phosphorylation Reverses Aggressive Cancer Phenotypes
Apostolidi, M., Vathiotis, I. A., Muthusamy, V., Gaule, P., Gassaway, B. M., Rimm, D. L., & Rinehart, J. (2023) · doi:10.1158/0008-5472.c.6512994.v1
乌尔肯, ·. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.13112580
Targeting CaMKII-δ/DHCR24 axis is a novel strategy against acute myeloid leukemiaPreprint
Wu, Z., Gong, Q., Li, M., Zheng, S., Zhang, X., Wang, P., Liang, Y., & Xu, R. (2024) · Research Square · doi:10.21203/rs.3.rs-3872938/v1
Zlatnik, E. Y., Enin, Y. S., Буров, О. Н., Bondarenko, E. S., Sagakyants, A. B., Kutilin, D. S., Dzigunova, Y. V., Novikova, I. A., & Przhedetskiy, Y. V. (2024) · South Russian Journal of Cancer · doi:10.37748/2686-9039-2024-5-3-5
Bahrami-Banan, F., Taherkhani, A., Najafi, R., Alizadeh, N., Ghadimipour, H., Barati, N., Derakhshandeh, K., & Soleimani, M. (2025) · Research in Pharmaceutical Sciences · doi:10.4103/rps.rps_128_23
“Moreover, it regulates the catalytic activity of pyruvate kinase M2 and 6-phosphofructokinase (78).”
Mao, J., Gan, Y., Tan, X., He, Y., Jing, Q., & Shi, Q. W. (2025) · International Journal of Women s Health · doi:10.2147/ijwh.s500632
“Cyclin-Dependent Kinase 6 (CDK6) is an important regulatory protein of the cell cycle and metabolism, 61 controlling cell growth, development, metabolism, inflammation and apoptosis.”
Bui, V. N., & Hà, C. H. (2025) · TAP CHI SINH HOC · doi:10.15625/2615-9023/22551
Optochemical control of G1 cell cycle by regulating CDK4/6 degradation
Wang, T., Zhang, Y., Liu, Y., Wang, L., Liu, L., & Wang, W. (2025) · iScience · doi:10.1016/j.isci.2025.113304
Faramayuda, F., Riyanti, S., Puspitasari, M., Ismail, N. K., Venando, J. B., Suryasaputra, D., Sukrasno, S., & Muttaqin, R. M. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5355053
COSTA, L. M. D., Ferreira, W. A. S., Machado, C. B., Amorim, C. K. N., BERG, A. V. V. D., FILHO, M. O. D. M., de Moraes, M. E. A., de Souza, L. E. B., Khayat, A. S., de Oliveira, E. H. C., et al. (2025) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20539
“ALL (26).”
Zhang, Z., Li, Y., Leturcq, M., Abula, Y., Wu, X., & Kimata, Y. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.13.675969
Cyclin Y Overexpression Drives a Fatal Metabolic Syndrome via Defective Glucose HomeostasisPreprint
López-Sainz, L. R., Ayala, E., Sánchez-Belmonte, A., Ortega, S., Caleiras, E. J., Zarzuela, E., Isasa, M., Santiveri, C. M., Campos‐Olivas, R., de Cárcer, G., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.15.694124
“Cyclin D3-CDK6 complexes on the other hand phosphorylate intermediates of glycolysis redirecting those to pentose phosphate pathway and serine pathways in cancer cells to produce antioxidant species counteracting reactive oxygen species production (Wang et al , 2017).”
Yang, K., Zhang, X., Chen, L., Chen, S., & Ji, Y. (2021) · Figshare · doi:10.6084/m9.figshare.13558854
Yang, K., Zhang, X., Chen, L., Chen, S., & Ji, Y. (2021) · Figshare · doi:10.6084/m9.figshare.13558851
Yang, K., Zhang, X., Chen, L., Chen, S., & Ji, Y. (2021) · Figshare · doi:10.6084/m9.figshare.13558866
Yang, K., Zhang, X., Chen, L., Chen, S., & Ji, Y. (2021) · Figshare · doi:10.6084/m9.figshare.13558848
Yang, K., Zhang, X., Chen, L., Chen, S., & Ji, Y. (2021) · Figshare · doi:10.6084/m9.figshare.13558860
Yang, K., Zhang, X., Chen, L., Chen, S., & Ji, Y. (2021) · Figshare · doi:10.6084/m9.figshare.13558857
Liu, Y., Tang, W., Ren, L., Liu, T., Yang, M., Wei, Y., Chen, Y., Ji, M., Chen, G., Chang, W., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19304840
Liu, Y., Tang, W., Ren, L., Liu, T., Yang, M., Wei, Y., Chen, Y., Ji, M., Chen, G., Chang, W., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19304837
Yang, K., Zhang, X., Chen, L., Chen, S., & Ji, Y. (2021) · Figshare · doi:10.6084/m9.figshare.13558863
Gao, J., Yang, Y., Chang, X., Wang, X., Zhang, Z., Shi, S., Liu, Y., Su, J., Chen, Z., Sun, R., et al. (2026) · Cancer Cell International · doi:10.1186/s12935-026-04171-z
“Another study on colorectal cancer discovered that CDK6 enhances glycolysis and that HK2 might be a potential downstream target of CDK6 [13].”
InfluentialGuo, S., Xu, L., Chen, Y., Zhao, Y., Zhang, Y., Yu, R., Cao, K., Wang, L., Ai, W., Luo, J., et al. (2026) · Circulation · doi:10.1161/circulationaha.125.075951 · Cited by 4
Ciblage thérapeutique de la protéine CDK6 dans les leucémies aiguës myéloïdes
Brault, L. M. (2022) · theses.fr (ABES) · doi:10.70675/26bca708z5a9az4d80z85bfz9159b330b1e8
The cell cycle machinery regulates glucose-6-phosphate dehydrogenase activity in maize
Lara‐Núñez, A., Guerrero-Molina, E. D., Labastida-Cuevas, R., Rodríguez‐Sotres, R., & Vázquez-Ramos, J. M. (2026) · Journal of Plant Physiology · doi:10.1016/j.jplph.2026.154843
Serpa-Gonçalves, I., & Serpa, J. (2026) · Advances in experimental medicine and biology · doi:10.1007/978-3-032-12166-0_1
Upadhyay, S., Khan, S., Bhardwaj, M., & Hassan, M. I. (2026) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2026.168364
Pan, X., Wang, S., Lai, K., Dong, H., Zheng, K., Shen, Y., Yu, A., Lin, C., & Gan, C. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110344
Zheng, S., Shen, Z., Wu, Y., Huang, X., Zhang, Z., Liu, J., Wei, Q., Chen, W., Chen, Y., & Xu, L. (2026) · MedComm · doi:10.1002/mco2.70898
“Cell cycle-regulatory CDKs (e.g., CDK1, CDK2, and CDK6) are able to directly phosphorylate metabolic enzymes to reshape bioenergetics [ 53, 72, 97 ], while transcription-associated CDKs (e.g., CDK7, CDK8, CDK9, and CDK12) govern metabolic gene expression networks mainly via modulating Pol II…”
The molecular mechanics of CDK4/6 inhibitors: resistance pathways and combination strategies
Dharavath, A., Mishra, B. B., & Guru, S. K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44611-5.00002-x
Yuan, J., Zhang, H., Huang, J., Wang, B., Wang, M., & Yang, L. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189733
BindingDB Entry 50010375: Discovery and SARs of 5-Chloro-
BindingDB (2021) · UC San Diego · doi:10.7270/q2n87f9b
BindingDB Entry 50017151: Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts.
BindingDB (2023) · UC San Diego · doi:10.7270/q2bv7mpd
BindingDB (2019) · UC San Diego · doi:10.7270/q2ks6tzk
Metadata
- Authors
- Wang, H., Nicolay, B. N., Chick, J. M., Gao, X., Geng, Y., Ren, H., Gao, H., Yang, G., Williams, J. A., Suski, J. M., Keibler, M. A., Sicinska, E., Gerdemann, U., Haining, W. N., Roberts, T. M., Polyak, K., Gygi, S. P., Dyson, N. J., & Sicinski, P.
- Affiliations
- Harvard University (US)
- Massachusetts General Hospital (US)
- Massachusetts Institute of Technology (US)
- Dana-Farber Cancer Institute (US)
- Broad Institute (US)
- ORCID
- Venue
- Nature
- Published
- 2017-06
- Volume
- 546
- Issue
- 7658
- Pages
- 426-430
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC5516959
- OpenAlex
- W2624626767
- Cited by
- 347
- References
- 37
- Citations by year
- 2026: 20 · 2025: 31 · 2024: 29 · 2023: 43 · 2022: 41 · 2021: 45 · 2020: 61 · 2019: 32 · 2018: 30 · 2017: 15
- FWCI
- 12.74
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- The Novartis Repository (Novartis) (submittedVersion)
- Funders
- National Cancer Institute (R01CA190509, P50CA090381, F32CA165856, T32CA009361, R01CA202634, P01CA080111, R01CA163698, R01CA083688)
- National Institute of General Medical Sciences (R01GM067945)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- cyclin D3, CDK6, cyclin-dependent kinases, tumor cell survival, glycolysis, 6-phosphofructokinase, PKM2, pentose phosphate pathway, serine pathway, NADPH, glutathione, reactive oxygen species, oxidative stress, apoptosis, CDK4/6 inhibitors, RB1, patient selection
- MeSH terms
- Aminopyridines, Animals, Cell Cycle, Cell Survival, Female, Glycolysis, Humans, Neoplasms, Pentose Phosphate Pathway, Phosphofructokinase-1, Phosphorylation, Purines, Pyruvate Kinase, Serine, Apoptosis, Reactive Oxygen Species, Oxidative Stress, Xenograft Model Antitumor Assays, Reactive Nitrogen Species, Cell Line, Tumor, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Mice, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Cyclin D3
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.